WO2002088181A3 - Mrp8/mrp14 heterodimer, or its individual components in combination, for treating and/or preventing skin diseases, wounds and/or wound-healing disturbances - Google Patents

Mrp8/mrp14 heterodimer, or its individual components in combination, for treating and/or preventing skin diseases, wounds and/or wound-healing disturbances Download PDF

Info

Publication number
WO2002088181A3
WO2002088181A3 PCT/EP2002/004765 EP0204765W WO02088181A3 WO 2002088181 A3 WO2002088181 A3 WO 2002088181A3 EP 0204765 W EP0204765 W EP 0204765W WO 02088181 A3 WO02088181 A3 WO 02088181A3
Authority
WO
WIPO (PCT)
Prior art keywords
mrp8
combination
individual components
wounds
mrp14
Prior art date
Application number
PCT/EP2002/004765
Other languages
French (fr)
Other versions
WO2002088181A2 (en
Inventor
Joern-Peter Halle
Andreas Goppelt
Original Assignee
Switch Biotech Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10121254A external-priority patent/DE10121254A1/en
Application filed by Switch Biotech Ag filed Critical Switch Biotech Ag
Priority to EP02732688A priority Critical patent/EP1390058A2/en
Priority to AU2002304710A priority patent/AU2002304710A1/en
Publication of WO2002088181A2 publication Critical patent/WO2002088181A2/en
Publication of WO2002088181A3 publication Critical patent/WO2002088181A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6881—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/20—Dermatological disorders

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Food Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The present invention relates to the use of an MRP8/MRP14 heterodimer, or of its individual components in combination, of at least one nucleic acid encoding the entire heterodimer or its individual components in combination, or of a cell which is expressing the entire heterodimer, or its individual components in combination, for treating and/or preventing skin diseases, wounds, and/or wound-healing disturbances which are characterized by a reduced quantity of MRP8/MRP14 heterodimers, in particular diabetes-associated wounds, and to methods for identifying pharmacologically active substances which exert an influence on the function or expression of MRP8/MRP14 heterodimers.
PCT/EP2002/004765 2001-04-30 2002-04-30 Mrp8/mrp14 heterodimer, or its individual components in combination, for treating and/or preventing skin diseases, wounds and/or wound-healing disturbances WO2002088181A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP02732688A EP1390058A2 (en) 2001-04-30 2002-04-30 Mrp8/mrp14 heterodimer, or its individual components in combination, for treating and/or preventing skin diseases, wounds and/or wound-healing disturbances
AU2002304710A AU2002304710A1 (en) 2001-04-30 2002-04-30 Mrp8/mrp14 heterodimer, or its individual components in combination, for treating and/or preventing skin diseases, wounds and/or wound-healing disturbances

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE10121254A DE10121254A1 (en) 2001-04-30 2001-04-30 Functional assay on the activity of human MRP8/MRP14 heterodimer, for diagnosing and treating skin diseases, wounds or wound-healing disturbances with reduced quantity of the heterodimer, in particular a diabetic ulcer
DE10121254.2 2001-04-30
US32292501P 2001-09-17 2001-09-17
US60/322,925 2001-09-17

Publications (2)

Publication Number Publication Date
WO2002088181A2 WO2002088181A2 (en) 2002-11-07
WO2002088181A3 true WO2002088181A3 (en) 2003-11-20

Family

ID=26009206

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2002/004765 WO2002088181A2 (en) 2001-04-30 2002-04-30 Mrp8/mrp14 heterodimer, or its individual components in combination, for treating and/or preventing skin diseases, wounds and/or wound-healing disturbances

Country Status (3)

Country Link
EP (1) EP1390058A2 (en)
AU (1) AU2002304710A1 (en)
WO (1) WO2002088181A2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003212246A1 (en) * 2002-02-15 2003-09-04 Johannes Roth Method for diagnosis of inflammatory diseases using mrp8/mrp14
US20070123455A1 (en) * 2003-04-04 2007-05-31 Joel Palefsky Immunomodulatory agents for treatment of inflammatory diseases
DE10324997A1 (en) * 2003-06-03 2004-12-23 Switch Biotech Ag Mrp8 / Mrp14 inhibitors and their use for the prevention and / or treatment of hypertrophic scars and keloids
CA2722909A1 (en) 2008-04-30 2009-11-05 Genomix Co., Ltd. Method for collecting functional cells in vivo with high efficiency
WO2009133939A1 (en) 2008-04-30 2009-11-05 株式会社ジェノミックス Agent for recruitment of bone-marrow-derived pluripotent stem cell into peripheral circulation
AU2009240885A1 (en) * 2008-04-30 2009-11-05 Genomix Co., Ltd. Pharmaceutical agent for promoting the functional regeneration of damaged tissue
AU2010312537A1 (en) * 2009-10-28 2012-05-17 Genomix Co., Ltd. Tissue-regeneration promoter using recruitment of bone marrow mesenchymal stem cells and/or pluripotent stem cells in blood
PT3358011T (en) 2011-04-26 2020-04-23 Univ Osaka Peptide for inducing regeneration of tissue and use thereof
NO336551B1 (en) * 2011-06-21 2015-09-28 Magne Fagerhol Improved ELISA for calprotectin in faecal or gastrointestinal tract test
RU2649069C2 (en) 2012-10-25 2018-04-02 Дженомикс Ко., Лтд. Novel method for treating spinal cord injury using hmgb1 fragment
AU2013335684B2 (en) 2012-10-25 2017-06-29 Osaka University Novel method for treating cardiac infarction using HMGB1 fragment
US11253570B2 (en) 2016-11-07 2022-02-22 Medizinische Hochschule Hannover (Mhh) S100A8/S100A9-induced immunotolerance in newborn subjects
US11298403B2 (en) 2017-12-01 2022-04-12 StemRIM Inc. Therapeutic agent for inflammatory bowel disease

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000018970A1 (en) * 1998-09-29 2000-04-06 Asahi Kasei Kabushiki Kaisha Method for controlling the release of granules
EP1114862A2 (en) * 1999-11-17 2001-07-11 Switch Biotech Aktiengesellschaft Use of polyeptides or their encoding nucleic acids for the diagnosis or treatment of skin diseases and their use in indentifying pharmacologically acitve substances

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000018970A1 (en) * 1998-09-29 2000-04-06 Asahi Kasei Kabushiki Kaisha Method for controlling the release of granules
EP1114862A2 (en) * 1999-11-17 2001-07-11 Switch Biotech Aktiengesellschaft Use of polyeptides or their encoding nucleic acids for the diagnosis or treatment of skin diseases and their use in indentifying pharmacologically acitve substances

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
AMBERG, R.: "Time-dependent cytokine expression in cutaneous wound-repair", RECHTSMEDIZINISCHE FORSCHUNGSERGEBNISSE (1996), 13(WOUND HEALING PROCESS: FORENSIC PATHOLOGICAL ASPECTS), 107-121, 1996, XP001121960 *
BITTNER M ET AL: "Identification of target genes for the development of innovative drugs to heal chronic wounds.", WOUND REPAIR AND REGENERATION, vol. 9, no. 2, March 2001 (2001-03-01), Eleventh Annual Meeting and Educational Symposium Wound Healing Society;Albuquerque, New Mexico, USA; May 16-18, 2001, pages 146, XP009004117, ISSN: 1067-1927 *
LI X ET AL: "Differential protein profile in the ear-punched tissue of regeneration and non-regeneration strains of mice: A novel approach to explore the candidate genes for soft-tissue regeneration.", BIOCHIMICA ET BIOPHYSICA ACTA, vol. 1524, no. 2-3, 2000, pages 102 - 109, XP002229131, ISSN: 0006-3002 *
THOREY IRMGARD S ET AL: "The Ca2+-binding proteins S100A8 and S100A9 are encoded by novel injury-regulated genes.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 276, no. 38, 21 September 2001 (2001-09-21), pages 35818 - 35825, XP002229132, ISSN: 0021-9258 *

Also Published As

Publication number Publication date
WO2002088181A2 (en) 2002-11-07
AU2002304710A1 (en) 2002-11-11
EP1390058A2 (en) 2004-02-25

Similar Documents

Publication Publication Date Title
WO2002088181A3 (en) Mrp8/mrp14 heterodimer, or its individual components in combination, for treating and/or preventing skin diseases, wounds and/or wound-healing disturbances
HK1034189A1 (en) An acidified composition for topical treatment of nail and skin conditions.
WO2004091370A3 (en) Method for stimulating angiogenesis and wound healing
ATE311371T1 (en) NON-PEPTIDE INHIBITORS OF VLA-4 DEPENDENT CELL BINDING FOR THE TREATMENT OF INFLAMMATION, AUTOIMMUNE DISEASES AND RESPIRATORY DISORDERS
DE69821520D1 (en) USE OF ALKYLATED IMINO SUGARS FOR THE TREATMENT OF MULTIPLE MEDICINE RESISTANCE
WO2002015920A3 (en) Treatment of hyperproliferative diseases
WO2006048877A3 (en) Treatment of b-cell malignancies with fgfr3 inhibitors
WO2005046614A3 (en) System for treating and preventing breast cancer
WO2004110392A3 (en) Compositions and methods for treating coronavirus infection and sars
WO2002049629A3 (en) Methods for reducing chronic stress in mammals
EP1114862A3 (en) Use of polyeptides or their encoding nucleic acids for the diagnosis or treatment of skin diseases and their use in indentifying pharmacologically acitve substances
ZA978400B (en) Use of inhibitors of the activity of retinoic acid to promote healing.
ATE499445T1 (en) HUMAN UBIQUITIN LIGASE E3. USE FOR MODULATION OF NF-KAPPA B
DK1419239T3 (en) Müllerian inhibitory drug levels and ovarian response
ATE291586T1 (en) HUMAN ANTIBIOTIC PROTEIN
WO2003072126A3 (en) Use of a fibroblast growth factor-binding protein for the treatment and diagnosis of diabetic wound healing problems
DE60118769D1 (en) USE OF LONG PENTRAXIN PTX3 TO TREAT DISEASES CAUSED BY CHANGED ACTIVITY OF THE FGF-2 GROWTH FACTOR
WO2006044107A3 (en) Method of treating human preeclampsia employing resibufagenin
WO2005028616A3 (en) Morphogen compositions and methods of use thereof to treat heart disorders
WO2004106519A3 (en) Mrp8/mrp14 inhibitors and the use thereof for preventing and/or treating hypertrophic scars and keloids
EP1568376A3 (en) Use of alpha-1 antichymotrypsin for the manufacture of a composition for treatment, prevention or diagnosis of poorly healing diabetic or arterial wounds
DE59805246D1 (en) TISSUE FACTOR INFLUENCING VASOCULAR FORMATION
ATE554393T1 (en) DIAGNOSTICS AND THERAPEUTICS FOR DISEASES ASSOCIATED WITH ADIPONECTIN RECEPTOR 2 (ADIPOR2).
DE59805215D1 (en) USE OF BROMELAIN PROTEASES TO INHIBIT BLOOD COagulation
DE50311184D1 (en) EG-VEGF / Prokineticin 2 receptor antagonists

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2002732688

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2002732688

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP

WWW Wipo information: withdrawn in national office

Ref document number: 2002732688

Country of ref document: EP